Original language | English |
---|---|
Article number | 103350 |
Pages (from-to) | 103350 |
Journal | International Journal of Drug Policy |
Volume | 97 |
DOIs | |
Publication status | Published - 1 Nov 2021 |
Access to Document
- https://doi.org/10.1016/j.drugpo.2021.103350Licence: Unspecified
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: International Journal of Drug Policy, Vol. 97, 103350, 01.11.2021, p. 103350.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Standard Units for cannabis dose: Why is it important to standardize cannabis dose for drug policy and how can we enhance its place on the public health agenda?
AU - Lopez-Pelayo, Hugo
AU - Matrai, Silvia
AU - Belcells-Olivero, Merce
AU - Campeny, Eugenia
AU - Braddick, Fleur
AU - Bossong, Matthijs G.
AU - Cruz, Olga S.
AU - Deluca, Paolo
AU - Geert, Dom
AU - Feingold, Daniel
AU - Freeman, Tom
AU - Guzman, Pablo
AU - Hindocha, Chandni
AU - Kelly, Brian C
AU - Liebregts, Nienke
AU - Lorenzetti, Valentina
AU - Manthey, Jakob
AU - Matias, Joao
AU - Oliveras, Clara
AU - Pons, Maria Teresa
AU - Rehm, Jürgen T
AU - Rosenkranz, Moritz
AU - Swithenbank, Zoe
AU - Deurse, Luc van
AU - Julian, Vicente
AU - Vuolo, Mike
AU - Wojnar, Marcin
AU - Gual, Antoni
N1 - Funding Information: This work is supported by the following institutions: Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Hospital Clínic i Universitari de Barcelona and CERCA Programme / Generalitat de Catalunya. Funding Information: Paolo Deluca is supported by the National Institute for Health Research (NIHR) Applied Research Collaboration South London (NIHR ARC South London) at King's College Hospital NHS Foundation Trust. The views expressed are those of the author[s] and not necessarily those of the NIHR or the Department of Health and Social Care, UK Funding Information: HLP: received funding from the Spanish Ministry of Economy and Competitiveness , Instituto de Salud Carlos III through a “Juan Rodes” contract ( JR19/00025 , to Dr. Hugo López-Pelayo), FEDER. Funding Information: FuturiZe is co-financed by grant N? 806964 under the European Union's DG Justice Programme "Drugs Policy Initiatives" - Supporting initiatives in the field of drugs policy (JUST-2017-AG-DRUGS) from 01/10/2018 to 31/3/2020.HLP: received funding from the Spanish Ministry of Economy and Competitiveness, Instituto de Salud Carlos III through a ?Juan Rodes? contract (JR19/00025, to Dr. Hugo L?pez-Pelayo), FEDER. Funding Information: This study is funded by the Spanish grant of Plan Nacional Sobre Drogas, Ministerio de Sanidad y Consumo (PNSD 132373 - 2017I053 - 603; Antoni Gual Solé). The conclusions of the article are only the responsibility of the authors and do not necessarily represent the official views of the institutions, who had no further role in study design, collection, analysis and interpretation of the data; in the writing of the paper; or in the decision to submit the paper for publication.
PY - 2021/11/1
Y1 - 2021/11/1
UR - http://www.scopus.com/inward/record.url?scp=85118575839&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.drugpo.2021.103350
DO - https://doi.org/10.1016/j.drugpo.2021.103350
M3 - Article
SN - 0955-3959
VL - 97
SP - 103350
JO - International Journal of Drug Policy
JF - International Journal of Drug Policy
M1 - 103350
ER -